The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy

Trimetazidine is a new metabolic antiischemic agent, which increases the tolerance of cardiomyocytes to ischemia. The aim of the study was to evaluate the effect of additional trimatazidine therapy in patients with ischemic cardiomyopathy (ICMP) in comparison with standard therapy of cardiac insuffi...

Full description

Saved in:

Bibliographic Details
Published in:	Klinicheskaia meditsina Vol. 84; no. 10; p. 55
Main Authors:	Sisakian, A S, Torgomian, A L, Barkhudarian, A L
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2006
Subjects:	Aged Cardiomyopathies - epidemiology Exercise Exercise Tolerance - drug effects Female Humans Hypertrophy, Left Ventricular - drug therapy Hypertrophy, Left Ventricular - epidemiology Male Middle Aged Myocardial Ischemia - epidemiology Trimetazidine - pharmacology Trimetazidine - therapeutic use Vasodilator Agents - pharmacology Vasodilator Agents - therapeutic use
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Trimetazidine is a new metabolic antiischemic agent, which increases the tolerance of cardiomyocytes to ischemia. The aim of the study was to evaluate the effect of additional trimatazidine therapy in patients with ischemic cardiomyopathy (ICMP) in comparison with standard therapy of cardiac insufficiency. According to the results of the study, trimetazidine improves the clinical status, functional class of cardiac insufficiency, left ventricular ejection fraction, in ICMP patients. Trimetazidine increases physical exercise tolerance according to the results of six-minute walking test. Thus, the optimization of myocardial energetic metabolism may be a promising perspective in the treatment of coronary heart disease with systolic dysfunction.
ISSN:	0023-2149